• Title/Summary/Keyword: levodopa

Search Result 41, Processing Time 0.021 seconds

A Case of Parkinson's Disease Patient with Nausea and Vomiting Induced by Taking Levodopa (레보도파 복용으로 유발된 오심 및 구토를 호소하는 파킨슨병 환자 한방 치험 1례)

  • Kim, Se-won;Yang, Jung-yun;Lee, Yu-jin;Cho, Ki-ho;Jung, Woo-sang;Kwon, Seung-won;Choi, Ki-mun;Mun, Sang-kwan
    • The Journal of Internal Korean Medicine
    • /
    • v.40 no.2
    • /
    • pp.246-253
    • /
    • 2019
  • Objective: In this care report, we address a case of a Parkinson's disease patient with nausea and vomiting. Methods: A patient was treated with Korean medicine therapies including herbal medication (Hyungbangjihwang-tang, Boikyangwie-tang), acupuncture, and electroacupuncture during 35 days of hospitalization. We evaluated the improvements of symptoms by checking the number of vomiting episodes and the presence of nausea. Results: During 35 days of Korean medicine treatment, there was improvement in patient's symptoms. The frequency of vomiting had decreased, and the nausea had decreased and not appeared for the last 7 days. Conclusions: This study suggested that Korean medicine therapies might be effective in relieving gastrointestinal symptoms of Parkinson's disease.

Proton MR Spectroscopic Changes in Parkinson′s Disease

  • 백현만;최보영;손병철;정성택;이형구;서태석
    • Proceedings of the KSMRM Conference
    • /
    • 2003.10a
    • /
    • pp.88-88
    • /
    • 2003
  • Purpose: To investigate whether there are significant changes in regional brain metabolism in patients with Parkinson's disease after thalamotomy using proton magnetic resonance spectroscopy (1H MRS). Materials and methods: Fifteen patients with Parkinson's disease of mean age 56.5 years (7 males and 8 females; mean age, 56.5 years) that have treated with levodopa were included. All patients with tremor experienced amelioration of their symptoms on the side contralateral to the thalamotomy. As a single-voxel technique, 1H MR spectra were obtained from the volume of interested regions in thalamus and primary motor cortex. Spectral parameters were: 20 ms TE, 2000 ms TR, 128 averages, 2500 Hz spectral width, and 2048 data points.

  • PDF

Overview of Periodic Limb Movements During Sleep (주기성 사지운동증의 개관)

  • Cyn, Jae-Gong
    • Sleep Medicine and Psychophysiology
    • /
    • v.15 no.1
    • /
    • pp.17-24
    • /
    • 2008
  • Periodic leg movements during sleep (PLMS) are best described as repetitive stereotypical movements of the lower extremities characterized by dorsiflexion of the ankle, dorsiflexion of the toes and a partial flexion of the knee and sometimes the hip. The prevalence of PLMS is about 5-11% in adults and is predicted much higher than previously surveyed. They are also frequently found in various sleep disorders, several disorders not primarily affecting sleep, and patients taking psychiatric medications. Although they are rarely found in children, they are common findings in children referred to a pediatric sleep laboratory. The pathophysiology is strongly associated with decline of central dopaminergic function and closely related to arousal system during sleep. Benzodiazepines, levodopa, dopamine agonists and opioids are generally recommended for treatment but more controlled studies on the effectiveness are needed.

  • PDF

Dopa-responsive dystonia with additional unusual clinical features: A case report confirmed by molecular genetics

  • Lee, Woong-Woo;Choi, Jong-Moon;Lee, Cha Gon
    • Journal of Genetic Medicine
    • /
    • v.17 no.1
    • /
    • pp.34-38
    • /
    • 2020
  • The term dopa-responsive dystonia (DRD) is used to describe a group of neurometabolic disorders, which are characterized by dystonia, and are typically associated with diurnal fluctuations and respond to levodopa treatment. Autosomal dominant DRD (DYT5a, MIM# 128230) is caused by a heterozygous mutation in the GTP cyclohydrolase 1 (GCH1) gene (MIM# 600225). GCH1 encodes an enzyme, which is involved in the biosynthesis of tetrahydrobiopterin, an essential co-factor for tyrosine hydroxylase. Herein, we report the case of a 16-year-old girl who was diagnosed with DYT5a. She exhibited additional unusual clinical features, including intellectual disability, depression, multiple skeletal anomalies, and short stature, which are not commonly observed in patients with DYT5a. The patient harbored a heterozygous missense variant, c.539A>C, p.Gln180Pro, in the GCH1 gene, which was identified by targeted gene panel analysis using next-generation sequencing.

Research Trends on Compounds that Promote Melanin Production Related to Hair Graying (모발 백발화와 관련된 melanin 생성을 촉진시키는 화합물의 연구동향)

  • Moon-Moo Kim
    • Journal of Life Science
    • /
    • v.33 no.5
    • /
    • pp.445-454
    • /
    • 2023
  • Hair graying is the result of a malfunction in the signaling pathways that control melanogenesis, and it is activated by UV light, melanocyte-stimulating hormone (MSH), stem cell factor (SCF), Wnt, and endothelin-1 (ET-1). To prevent hair graying, synthetic and natural compounds can be used to stimulate melanogenesis effectively under the control of tyrosinase, tyrosine hydroxylase, tyrosinase-related protein-1 (TRP-1), TRP-2, and microphthalmia-associated transcription factor (MITF). This article describes a crucial strategy to resolve the problem of hair graying, as well as recent advances in the signaling pathway related to melanogenesis and hair graying. In particular, the article reviews potentially effective therapeutic agents that promote melanogenesis, such as antioxidants that modulate catalase, methionine sulfoxide reductase, and sirtuin 1 (SIRT1) activators including resveratrol, fisetin, quercetin, and ginsenoside. It also discusses vitiligo inhibitors, such as corticosteroids, calcineurin inhibitors, and palmitic acid methyl ester, as well as activators of telomerase expression and activity, including estrogen, androgen, progesterone, and dihydrotestosterone. Furthermore, it explores compounds that can inhibit hair graying, such as latanoprost, erlotinib, imatinib, tamoxifen, and levodopa. In conclusion, this article focuses on recent research trends on compounds that promote melanin production related to hair graying.

Comparative Homology Modeling and Ligand Docking Study of Human Catechol-O-Methyltransferase for Antiparkinson Drug Design

  • Lee, Jee-Young;Kim, Yang-Mee
    • Bulletin of the Korean Chemical Society
    • /
    • v.26 no.11
    • /
    • pp.1695-1700
    • /
    • 2005
  • Catechol-O-methyltransferase (COMT, EC 2.1.1.6) is an S-adenosylmethionine (SAM, AdoMet) dependent methyltransferase, and is related to the functions of the neurotransmitters in various mental processes, such as Parkinson’s disease. COMT inhibitors represent a new class of antiparkinson drugs, when they are coadministered with levodopa. Based on x-ray structure of rat COMT (rCOMT), the three dimensional structure of human COMT (hCOMT) was constructed by comparative homology modeling using MODELLER. The catalytic site of these two proteins showed subtle differences, but these differences are important to determine the characterization of COMT inhibitor. Ligand docking study is carried out for complex of hCOMT and COMT inhibitors using AutoDock. Among fifteen inhibitors chosen from world patent, nine models were energetically favorable. The average value of heavy atomic RMSD was 1.5 $\AA$. Analysis of ligand-protein binding model implies that Arg201 on hCOMT plays important roles in the interactions with COMT inhibitors. This study may give insight to develop new ways of antiparkinson drug.

Proton MR Spectroscopic Changes in Parkinson's Disease

  • 백현만;최보영;손병철;정성택;이형구;서태석
    • Proceedings of the Korean Society of Medical Physics Conference
    • /
    • 2003.09a
    • /
    • pp.74-74
    • /
    • 2003
  • Purpose: To investigate whether there are significant changes in regional brain metabolism in patients with Parkinson's disease after thalamotomy using proton magnetic resonance spectroscopy (lH MRS). Methods: Fifteen patients with Parkinson's disease of mean age 56.5 years (7 males and 8 females; mean age, 56.5 years) that have treated with levodopa were included. All patients with tremor experienced amelioration of their symptoms on the side contralateral to the thalamotomy. As a single-voxel technique, 1H MR spectra were obtained from the volume of interested regions in thalamus and primary motor cortex. Spectral parameters were: 20 ms TE, 2000 ms TR, 128 averages, 2500 Hz spectral width, and 2048 data points. Results: We found that NAA/Cho ratios showed generally low levels in thalamus in Parkinson's disease patients with clinical improvement following thalamotomy. Conclusions: 1H MRS may be a useful utility for the aid in better understanding the pathophy-siologic process in Parkinson's disease patients on the basis of the variation of NAA/Cho ratio. Acknowledgement: This study was supported by a grant of the Center for Functional and Metabolic Imaging Technology, Ministry of Health & Welfare, Republic of Korea (02-PJ3-PG6-EV07-0002).

  • PDF

L-DOPA Synthesis Using Tyrosinase-immobilized on Electrode Surfaces

  • Rahman, Siti Fauziyah;Gobikhrisnan, Siramulu;Gozan, Misri;Jong, Gwi Taek;Park, Don-Hee
    • Korean Chemical Engineering Research
    • /
    • v.54 no.6
    • /
    • pp.817-821
    • /
    • 2016
  • Levodopa or L-3,4-dihydroxyphenylalanine (L-DOPA) is the direct precursor of the neurotransmitter dopamine. L-DOPA is a well-known neuroprotective agent for the treatment of Parkinson's disease symptoms. L-DOPA was synthesized using the enzyme, tyrosinase, as a biocatalyst for the conversion of L-tyrosine to L-DOPA and an electrochemical method for reducing L-DOPAquinone, the product resulting from enzymatic synthesis, to L-DOPA. In this study, three electrode systems were used: A glassy carbon electrode (GCE) as working electrode, a platinum, and a Ag/AgCl electrode as auxiliary and reference electrodes, respectively. GCE has been modified using electropolymerization of pyrrole to facilitate the electron transfer process and immobilize tyrosinase. Optimum conditions for the electropolymerization modified electrode were a temperature of $30^{\circ}C$ and a pH of 7 producing L-DOPA concentration 0.315 mM. After 40 days, the relative activity of an enzyme for electropolymerization remained 38.6%, respectively.

Clinical Findings of 6-pyruvoyl-tetrahydropterins Synthase (PTPS) Deficiency in Korea (6-pyruvoyl-tetrahydropterins Synthase 결핍증의 임상적 고찰)

  • Yi, Youngsuk;Phil, Bae Seong;Lee, Jeong Ho;Lee, Dong Hwan
    • Journal of The Korean Society of Inherited Metabolic disease
    • /
    • v.13 no.1
    • /
    • pp.30-36
    • /
    • 2013
  • 6-pyruvoyltetrahydropterin synthase (PTPS) deficiency is autosomal recessive disorder and the most common type of tetrahydrobiopterin (BH4) deficiency. It is caused by deficiency of PTPS, a cofactor involved in the biosynthesis of BH4 from guanosine triphosphate (GTP). Unlike classical phenylketonuria, which needs restriction of dietary phenylalanine for whole life, BH4 deficiency is treated by tetrahydrobiopterin, levodopa, and 5-hydroxytryptophan replacement. So it is important to make accurate diagnosis and initiate treatment as soon as possible for a better prognosis. There is no retrospective study of Korean patients undergoing long-term treatment for PTPS deficiency. We report 9 Korean patients with PTPS deficiency and their laboratory findings including BH4 loading tests, urine pterin tests, genotypes, dihydropteridine reductase (DHPR) activities and clinical manifestations including medication and developmental delay existence.

  • PDF